Choose language

en
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

English
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

How do you prefer to top up your account?

* We don't charge any commission for making deposits into your account

Kymera Therapeutics Inc.

KYMR.US $ 60.33 USD

-0.1 $ (-0.17%)

Growth potential

28.96%

Dividend income

1d
1w
1mo
6mths
All the time

Add to cart

1 lot = 1 stock

Purchase amount:

Brokerage commission:

Transfer commission:

Recommendation

Buy

Performance Rating

DCF

-

ROE

-0.16

ROA

-0.09

P/S

38.23

P/B

4.58

Debt / Equity

-

About Company

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.


Sign up for investment ideas from Freedom Finance analysts

We will send an e-mail once a week containing only the most relevant and important information

Congratulations!

Now you will always be aware of which stocks are more profitable to invest in